This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MGEN Miragen Therapeutics (MGEN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Miragen Therapeutics Stock (NASDAQ:MGEN) 30 days 90 days 365 days Advanced Chart Get Miragen Therapeutics alerts:Sign Up Key Stats Today's Range$14.46▼$14.8650-Day Range$14.34▼$23.0152-Week Range$4.66▼$34.05Volume396,786 shsAverage Volume134,027 shsMarket Capitalization$57.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.Read More… Receive MGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGEN Stock News HeadlinesAmgen and MediLink to collaborate on SCLC combination therapyOctober 10, 2024 | msn.comWhy Biotech Giant Amgen Stands A Chance Of Taking On Novo, Lilly In ObesityAugust 7, 2024 | msn.comTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift all boats equally. They're wrong. One project stands to benefit more than any other – not by accident, but seemingly by design. June 7, 2025 | Crypto 101 Media (Ad)AMGN Earnings: Amgen Stock Down on Mixed Q2 ResultsAugust 7, 2024 | msn.comAmgen Undercuts Its Buy Point On Mixed Second-Quarter ReportAugust 6, 2024 | msn.comMiragen Therapeutics is about to announce earnings — here's what Wall Street expectsMay 7, 2024 | markets.businessinsider.comViridian Therapeutics Inc (VRDN)January 30, 2024 | investing.comSee More Headlines MGEN Stock Analysis - Frequently Asked Questions How were Miragen Therapeutics' earnings last quarter? Miragen Therapeutics, Inc. (NASDAQ:MGEN) announced its earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative trailing twelve-month return on equity of 141.66%. What other stocks do shareholders of Miragen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Miragen Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Nokia Oyj (NOK), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX) and Pfizer (PFE). Company Calendar Last Earnings11/10/2020Today6/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Laboratories Sub-IndustryN/A Current SymbolNASDAQ:MGEN CIK1590750 Webwww.signalgenetics.com Phone720-643-5200FaxN/AEmployees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($20.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.87 million Net Margins-1,393.50% Pretax MarginN/A Return on Equity-141.66% Return on Assets-88.74% Debt Debt-to-Equity Ratio0.20 Current Ratio4.23 Quick Ratio4.23 Sales & Book Value Annual Sales$4.46 million Price / Sales12.86 Cash FlowN/A Price / Cash FlowN/A Book Value$6.78 per share Price / Book2.17Miscellaneous Outstanding Shares3,908,000Free FloatN/AMarket Cap$57.37 million OptionableNot Optionable Beta1.66 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:MGEN) was last updated on 6/7/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s Wealth Reset: Could You Be The First Beneficiary?Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.